Market revenue in 2023 | USD 59.4 million |
Market revenue in 2030 | USD 110.3 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.18% in 2023. Horizon Databook has segmented the Thailand blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
In Thailand, the blood cancer diagnostics market is witnessing growth driven by several factors, such as increasing awareness about early blood cancer diagnosis, advancements in diagnostic technologies, and a rising incidence of blood cancer. The market is supported by the country's healthcare infrastructure and the availability of skilled healthcare professionals.
Public health campaigns and initiatives promoting diagnostic practices are contributing to early detection & diagnosis. Moreover, the adoption of advanced diagnostic tools, including liquid biopsy tests and digital imaging systems, is enhancing the accuracy & efficiency of blood cancer diagnostics in Thailand.
For instance, in November 2023, N Gene Bio, a South Korean biotechnology company, received marketing authorization from the Thai Food and Drug Administration (TFDA) for its Hemeac cutest blood cancer precision diagnostic panel.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Thailand blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account